ITM Trademark

Trademark Overview


On Tuesday, July 28, 2020, a trademark application was filed for ITM with the United States Patent and Trademark Office. The USPTO has given the ITM trademark a serial number of 79295830. The federal status of this trademark filing is REGISTERED as of Tuesday, June 15, 2021. This trademark is owned by ITM Isotopen Technologien München AG. The ITM trademark is filed in the Pharmaceutical Products, Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioa...

Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes

Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]

Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology
itm

General Information


Serial Number79295830
Word MarkITM
Filing DateTuesday, July 28, 2020
Status700 - REGISTERED
Status DateTuesday, June 15, 2021
Registration Number6383045
Registration DateTuesday, June 15, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 30, 2021

Trademark Statements


Goods and ServicesRadiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnostic purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases
Goods and ServicesMedical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes
Goods and ServicesConducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]
Goods and ServicesMedical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 19, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateMonday, October 19, 2020
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 19, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 19, 2020
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameITM Isotope Technologies Munich SE
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressDE

Party NameITM Isotopen Technologien München AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressDE

Party NameITM Isotopen Technologien München AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressDE

Trademark Events


Event DateEvent Description
Friday, November 26, 2021CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, November 15, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, October 21, 2021NEW REPRESENTATIVE AT IB RECEIVED
Monday, October 4, 2021GENERIC MADRID TRANSACTION SENT TO IB
Monday, October 4, 2021GENERIC MADRID TRANSACTION CREATED
Wednesday, September 15, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 15, 2021REGISTERED-PRINCIPAL REGISTER
Monday, April 5, 2021NOTIFICATION PROCESSED BY IB
Tuesday, March 30, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 30, 2021PUBLISHED FOR OPPOSITION
Monday, March 15, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 10, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 23, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 23, 2021EXAMINER'S AMENDMENT ENTERED
Tuesday, February 23, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, February 23, 2021EXAMINERS AMENDMENT E-MAILED
Tuesday, February 23, 2021EXAMINERS AMENDMENT -WRITTEN
Friday, February 12, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, February 12, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 12, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 12, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 12, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, February 14, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 12, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 12, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, December 27, 2020REFUSAL PROCESSED BY IB
Friday, December 4, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, December 4, 2020REFUSAL PROCESSED BY MPU
Friday, November 20, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, November 19, 2020NON-FINAL ACTION WRITTEN
Monday, November 16, 2020ASSIGNED TO EXAMINER
Friday, October 23, 2020APPLICATION FILING RECEIPT MAILED
Monday, October 19, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 15, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB